BioRestorative Therapies
Develops autologous cell therapies and cell-secretome cosmetics for spine and metabolic applications.
Something off on this page? Send us feedback.
Profile
Develops an investigational autologous cell therapy for chronic lumbar disc disease and a preclinical metabolic platform, while supplying a cell-secretome cosmetics product and earning licensing royalties. Operations combine internal cell manufacturing with outside trial partners and a private-label distribution relationship.
Develops BRTX-100, an investigational autologous cell therapy for chronic lumbar disc disease, alongside the preclinical ThermoStem metabolic platform. BRTX-100 uses a patient's bone-marrow mesenchymal stem cells, cultured under low-oxygen conditions and injected into damaged intervertebral discs.
Operates research and clinical manufacturing in Melville, New York, processing its lead therapy and making a cell-secretome cosmetic product supplied through Cartessa's Chronos ExoCR private-label channel. It also earns royalties from sublicensed disc and spine intellectual property.
Progress depends on FDA authorization, trial execution by outside clinical partners, licensed disc and spine technology, patient-specific manufacturing, and financing. The lead study remains blinded, with no efficacy results reported.
Company facts
Key statistics
Year to date −83.6% · Average volume (30d) 305.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 14, 2026Q1 FY26 | −$0.30 | −$0.19 | +36.7% | $312.5K | $23.2K | −92.6% | +1.75% |
| Mar 26, 2026Q4 FY25 | −$0.37 | −$0.37 | 0.0% | $150.0K | $20.0K | −86.7% | +0.41% |
| Nov 12, 2025Q3 FY25 | −$0.36 | −$0.33 | +8.3% | $460.0K | $11.8K | −97.4% | −9.42% |
| Aug 12, 2025Q2 FY25 | −$0.41 | −$0.30 | +26.8% | $200.0K | $303.3K | +51.7% | +2.04% |
Financial highlights
| 12 quarters | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $43.3K | $25.0K | $303.3K | $11.8K | $19.6K | $23.2K | |
| Gross profit | $40.0K | $22.1K | $294.6K | $1.2K | $18.0K | $15.8K | |
| Operating income | −$2.7M | −$4.8M | −$3.3M | −$3.7M | −$3.8M | −$3.4M | |
| Net income | −$1.6M | −$5.3M | −$2.7M | −$3.0M | −$3.2M | −$2.2M | |
| Diluted EPS | −$0.21 | −$0.64 | −$0.30 | −$0.33 | −$0.36 | −$0.24 | |
| Gross margin | 92.3% | 88.4% | 97.1% | 10.4% | 91.7% | 68.1% | |
| Operating margin | -6,212.8% | -19,230.1% | -1,089.8% | -31,432.3% | -19,516.8% | -14,612.6% |
Fiscal years (4-quarter sums)FY21 $46.0K · FY22 $119.8K · FY23 $145.8K · FY24 $401.0K · FY25 $359.7K
Revenue by product · Q1 FY26
Balance sheet, Mar 31, 2026Cash & short-term investments $3.6M · Total debt $34.5K · Total assets $4.6M · Shareholders' equity $3.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 25.48M · Float 23.76M · 93.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Auctus Fund, LLC | 2.70M | 9.90% | 13G | May 15, 2026 |
| Alta Partners LLC | 1.79M | 7.70% | 13G | Feb 13, 2026 |
| Silva, Francisco | 1.20M | 15.10% | 13D | Feb 19, 2025 |
| Citadel Advisors LLC | 238.6K | 0.94% | 13F | May 15, 2026 |
| Geode Capital Management, LLC | 223.1K | 0.88% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Mesoblast (ADR)
Intradiscal cell-therapy rival in chronic lumbar disc disease.
- Novo Nordisk (ADR)
Marketed GLP-1 drugs dominate obesity and type 2 diabetes care.
- Eli Lilly
Zepbound and Mounjaro address the same metabolic populations.
- Viking Therapeutics
Late-stage obesity candidate targets the future metabolic market.
- Altimmune
Dual GLP-1/glucagon candidate overlaps prospective obesity care.
- Sanofi (ADR)
Established diabetes therapies overlap prospective metabolic indications.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioRestorative Therapies | $0.2001 | 0.00% | $5.1M | — | — | 14.2 | −7.3% |
| Mesoblast (ADR) | $17.44 | −0.17% | $2.26B | — | — | 35.0 | +882.8% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Viking Therapeutics | $32.24 | +0.31% | $3.75B | — | — | — | — |
| Altimmune | $3.12 | −0.12% | $604.8M | — | — | 19,510.1 | +820.0% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Median | 39.4 | 23.6 | 13.9 | +47.7% |